Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine June 2011, 52 (6) 11A-12A;
  • Article
  • Info & Metrics
  • PDF
Loading

Somatostatin receptor targeting: Maecke and Reubi review the development, current status, and future potential of diagnostic and therapeutic targeting of neuroendocrine tumors with radiolabeled probes.Page 841

Cell-level dosimetry and biologic response: Zanzonico looks at the challenges that nonuniformity poses for radionuclide dose–response and dose–toxicity predictions and previews a related article in this issue of JNM.Page 845

PET and incident PD dementia: Bohnen and colleagues describe a longitudinal study using 18F-FDG PET to assess early regional cerebral subcortical and cortical metabolic changes underlying incident dementia in individuals with Parkinson disease.Page 848

Figure

PET and antiangiogenic HGG treatment: Hutterer and colleagues compare MRI assessment with metabolic 18F-FET PET response evaluation during antiangiogenic treatment in patients with recurrent high-grade glioma.Page 856

Figure

Dual-time-point PET in brain tumors: Prieto and colleagues evaluate a method for dual-time-point 18F-FDG PET imaging for high-grade brain tumor detection and delineation using quantitative criteria applied on a voxel basis.Page 865

Figure

Myocardial perfusion reserve and revascularization: Slart and colleagues investigate whether myocardial perfusion reserve is related to survival in patients with ischemic heart disease after revascularization/viability assessment with gated 18F-FDG PET.Page 873

PET and tuberculosis in HIV: Sathekge and colleagues report on a pilot study of relationships between severity of tuberculosis as assessed by 18F-FDG PET at diagnosis and response to treatment in a group of patients with HIV.Page 880

Pancreatic uptake of 68Ga-DOTANOC: Castellucci and colleagues assess the incidence of increased uptake of this somatostatin analog radiotracer in the head of the pancreas after serial PET/CT in a large population of patients with extrapancreatic neuroendocrine tumors.Page 886

Figure

90Y-ibritumomab tiuxetan after ASCT: Ria and colleagues describe the results of this targeted radioimmunotherapy approach as consolidated therapy after autologous stem cell transplantation in patients with CD20-positive, aggressive non-Hodgkin lymphoma.Page 891

Figure

Long-term 131I-tositumomab results: Buchegger and colleagues provide an encouraging 10-y update on the safety and efficacy of this radioimmunotherapy in patients with relapsed or resistant indolent or transformed non-Hodgkin lymphoma.Page 896

Marrow visualization on kidney scans: Shapoval and colleagues look at the frequency of bone marrow visualization in 99mTc-MAG3 renal scans and its association with various laboratory parameters.Page 901

Nuclear medicine in infancy: Treves and colleagues provide an educational overview of imaging in children younger than 1 y, including clinical indications, methods, patient handling/positioning, sedation, radiopharmaceutical dosages, instrumentation, and radiation exposures and risk.Page 905

Modeling response to lognormal uptake: Rajon and colleagues use a 3-dimensional model of cells in a heterogeneous carbon scaffold to assess the effects of nonuniformity of radioactivity among cells on dose response.Page 926

Figure

18F-PEG6-IPQA PET: Tian and colleagues determine in nonhuman primates the pharmacokinetics, biodistribution, metabolism, and radiation dosimetry of this radiotracer created for factor receptor kinase–expressing non–small cell lung cancer xenografts.Page 934

DR5 PET tracer: Rossin and colleagues characterize the potential of 64Cu-labeled conatumumab, a fully human monoclonal antibody that binds to and activates human death receptor 5, as a PET tracer for imaging DR5 in tumors.Page 942

Figure

Changes in P-gp function: Takashima and colleagues investigate developmental changes in P-glycoprotein function in the blood–brain barrier of nonhuman primates using PET with R-11C-verapamil and 11C-oseltamivir, with implications for drug response studies in children and adults.Page 950

Multimodal apoptosis imaging: Zhang and colleagues report on the development and evaluation of annexin A5-conjugated polymeric micelles for dual SPECT and optical fluorescence detection of apoptosis.Page 958

Figure

FBnTP after transient coronary occlusion: Higuchi and colleagues determine the stability of perfusion defect size over time and the magnitude of redistribution of this 18F-labeled myocardial perfusion PET agent in a rat model.Page 965

Figure

131I-N,N-dimethyltryptamine in the brain: Vitale and colleagues explore the relationship between this strong psychodysleptic drug and hallucinogenic processes through comparison with tryptamine in small-animal imaging, biodistribution, and pharmacokinetic studies.Page 970

Copolymer agent for hepatocyte imaging: Yang and colleagues synthesize and characterize galactose-carrying copolymers with hydrazinonicotinamide chains as bifunctional groups for 99mTc-labeled SPECT targeting of specific hepatocytes.Page 978

PET and CXCR4 expression: De Silva and colleagues evaluate a positron-emitting monocyclam analog in subcutaneous brain tumors stably expressing this chemokine receptor and in colon tumors using dynamic and whole-body PET.Page 986

ABNM position statement: Frey and members of the American Board of Nuclear Medicine offer a definition of the scope of nuclear medicine practice and core professional competencies required now and for the future.Page 994

Report of ACR–SNM Task Force: Guiberteau and Graham report on the conclusions of a joint specialty effort to define current issues and develop recommendations for resident training in the rapidly evolving discipline of molecular imaging.Page 998

ON THE COVER

A study of the use of 64Cu-AMD3465 as a PET imaging agent has shown it capable of detecting lesions in a CXCR4-dependent fashion with high tumor-to-muscle ratios. In the PET/CT images shown here, CXCR4 expression in subcutaneous U87 brain tumor xenografts is seen. This positron-emitting monocyclam analog may serve as a suitable scaffold for the synthesis of clinically translatable imaging agents.See page 989.

Figure
  • © 2011 by Society of Nuclear Medicine
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (6)
Journal of Nuclear Medicine
Vol. 52, Issue 6
June 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jun 2011, 52 (6) 11A-12A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jun 2011, 52 (6) 11A-12A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • ON THE COVER
  • Info & Metrics
  • PDF

Related Articles

  • ACR-SNM Task Force on Nuclear Medicine Training: Report of the Task Force
  • Use of 18F-FDG PET to Predict Response to First-Line Tuberculostatics in HIV-Associated Tuberculosis
  • Copolymer-Based Hepatocyte Asialoglycoprotein Receptor Targeting Agent for SPECT
  • Characterization of 64Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5
  • Annexin A5–Conjugated Polymeric Micelles for Dual SPECT and Optical Detection of Apoptosis
  • Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study
  • Whole-Body Biodistribution Kinetics, Metabolism, and Radiation Dosimetry Estimates of 18F-PEG6-IPQA in Nonhuman Primates
  • Developmental Changes in P-Glycoprotein Function in the Blood–Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir
  • Imaging CXCR4 Expression in Human Cancer Xenografts: Evaluation of Monocyclam 64Cu-AMD3465
  • Marrow Visualization on Renal Scintigraphy: An Often-Overlooked Finding in Azotemic Patients
  • In Vivo Long-Term Kinetics of Radiolabeled N,N-Dimethyltryptamine and Tryptamine
  • 90Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma
  • Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
  • Voxel-Based Analysis of Dual-Time-Point 18F-FDG PET Images for Brain Tumor Identification and Delineation
  • Lognormal Distribution of Cellular Uptake of Radioactivity: Monte Carlo Simulation of Irradiation and Cell Killing in 3-Dimensional Populations in Carbon Scaffolds
  • Myocardial Perfusion Reserve After a PET-Driven Revascularization Procedure: A Strong Prognostic Factor
  • Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission
  • ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice
  • Stable Delineation of the Ischemic Area by the PET Perfusion Tracer 18F-Fluorobenzyl Triphenyl Phosphonium After Transient Coronary Occlusion
  • Cell-Level Dosimetry and Biologic Response Modeling of Heterogeneously Distributed Radionuclides: A Step Forward
  • O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma
  • Nuclear Medicine in the First Year of Life
  • Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire